<p>Omeros Corporation（纳斯达克代码：OMER - 获取免费报告）在周五的交易中出现了异常高的交易量。大约有 1,781,410 股在交易中易手，比前一交易日的 1,724,296 股增加了 3%。该股票最后交易价格为 14.4530 美元，之前收盘价为 15.36 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>你需要了解的突破性动量股</li>
</ul>
<p>OMER 最近成为几份研究报告的主题。WBB 证券在 10 月 15 日（星期三）的报告中重新发布了 “强力买入” 评级，并将 Omeros 的目标价格设定为 45.00 美元。Weiss 评级在 10 月 8 日（星期三）的报告中重新发布了 Omeros 的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 10 月 15 日（星期三）的研究报告中重申了 Omeros 的 “持有” 评级。D. Boral Capital 在一份研究报告中重申了 “买入” 评级，并对 Omeros 的目标价格设定为 36.00 美元。最后，HC Wainwright 在一份报告中重申了 Omeros 的 “买入” 评级。一位投资分析师对该股票给予了强力买入评级，两位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Omeros 的共识评级为 “适度买入”，共识目标价格为 33.67 美元。</p>
<p><strong>阅读我们关于 OMER 的最新报告</strong></p>
<h2>Omeros 股票下跌 5.1%</h2>
<p>该公司的市值为 10.3 亿美元，市盈率为-7.21，贝塔值为 2.48。该股票的 50 日移动平均价格为 8.91 美元，200 日移动平均价格为 5.73 美元。</p>
<p>Omeros（纳斯达克代码：OMER - 获取免费报告）最近在 11 月 13 日（星期四）发布了季度财报。这家生物制药公司报告的每股收益为（0.19 美元），超出市场共识预期的（0.58 美元）0.39 美元。整体来看，股票分析师预测 Omeros Corporation 在当前财政年度的每股收益将为-3.09 美元。</p>
<h2>对 Omeros 的对冲基金看法</h2>
<p>对冲基金最近对该公司的持仓进行了调整。拉塞尔投资集团在第三季度将其在 Omeros 的持仓增加了 113.1%。拉塞尔投资集团现在拥有 10,695 股这家生物制药公司的股票，价值 44,000 美元，此前在上个季度又购买了 5,677 股。Trexquant Investment LP 在第一季度购买了 Omeros 的新股份，价值 88,000 美元。B. Riley Wealth Advisors Inc.在第二季度收购了 Omeros 的新股份，价值约 32,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Omeros 的持仓增加了 829.6%。Tower Research Capital LLC TRC 现在拥有 13,414 股这家生物制药公司的股票，价值 40,000 美元，此前在上个季度又购买了 11,971 股。最后，Sei Investments Co.在第二季度收购了 Omeros 的新股份，价值约 40,000 美元。机构投资者和对冲基金持有该公司 48.79% 的股票。</p>
<h2>关于 Omeros</h2>
<p>（获取免费报告）</p>
<p>Omeros Corporation 是一家临床阶段的生物制药公司，专注于小分子和蛋白质治疗药物的发现、开发和商业化。该公司的研究项目针对炎症、补体介导的疾病和中枢神经系统疾病。Omeros 的产品组合包括内部发现的分子和生物制剂，反映了其推进满足医疗需求高的疾病治疗的承诺。</p>
<p>Omeros 首个获得 FDA 批准的产品 Omidria®（苯肾上腺素和氟氯噻吨眼内溶液）旨在通过防止手术中瞳孔缩小和减少接受白内障手术患者的术后疼痛来维持瞳孔大小。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票比 Omeros 更好</li>
<li>华盛顿为战争做准备</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>Nvidia x 1,000,000</li>
<li>在美国鬼城发现了 100 万亿美元的 “人工智能金属”</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票【不是 NVDA】</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Omeros 吗？</h2>
<p>在你考虑 Omeros 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Omeros 并不在名单上。</p>
<p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

奥麦罗制药

<p>Omeros Corporation（纳斯达克代码：OMER）经历了显著的交易量增加，交易量达到 1,781,410 股，比前一交易日上升了 3%。股价从$15.36 下跌至$14.4530。分析师的评级各不相同：一项强烈买入，两项买入，一项持有和一项卖出，整体评级为适度买入，目标价为$33.67。该公司报告的季度收益好于预期，市值为 10.3 亿美元。对冲基金正在调整其在该股票上的持仓</p>

<p>Omeros Corporation (NASDAQ:OMER - Get Free Report) saw unusually-high trading volume on Friday . Approximately 1,781,410 shares traded hands during trading, an increase of 3% from the previous session's volume of 1,724,296 shares.The stock last traded at $14.4530 and had previously closed at $15.36.</p>
<div class="lb-trans"><p>Omeros Corporation（纳斯达克代码：OMER - 获取免费报告）在周五的交易中出现了异常高的交易量。大约有 1,781,410 股在交易中易手，比前一交易日的 1,724,296 股增加了 3%。该股票最后交易价格为 14.4530 美元，之前收盘价为 15.36 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Breakout Momentum Plays You Need to Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你需要了解的突破性动量股</li>
</ul>
</div><p>OMER has been the subject of several recent research reports. WBB Securities reissued a &#34;strong-buy&#34; rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Omeros in a report on Wednesday, October 8th. Needham &amp; Company LLC reiterated a &#34;hold&#34; rating on shares of Omeros in a research report on Wednesday, October 15th. D. Boral Capital restated a &#34;buy&#34; rating and issued a $36.00 price objective on shares of Omeros in a research report on Wednesday. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating on shares of Omeros in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Omeros has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $33.67.</p>
<div class="lb-trans"><p>OMER 最近成为几份研究报告的主题。WBB 证券在 10 月 15 日（星期三）的报告中重新发布了 “强力买入” 评级，并将 Omeros 的目标价格设定为 45.00 美元。Weiss 评级在 10 月 8 日（星期三）的报告中重新发布了 Omeros 的 “卖出（d-）” 评级。Needham &amp; Company LLC 在 10 月 15 日（星期三）的研究报告中重申了 Omeros 的 “持有” 评级。D. Boral Capital 在一份研究报告中重申了 “买入” 评级，并对 Omeros 的目标价格设定为 36.00 美元。最后，HC Wainwright 在一份报告中重申了 Omeros 的 “买入” 评级。一位投资分析师对该股票给予了强力买入评级，两位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Omeros 的共识评级为 “适度买入”，共识目标价格为 33.67 美元。</p>
</div><p><strong>Read Our Latest Report on OMER</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 OMER 的最新报告</strong></p>
</div><h2>Omeros Stock Down 5.1%</h2>
<div class="lb-trans"><h2>Omeros 股票下跌 5.1%</h2>
</div><p>The firm has a market capitalization of $1.03 billion, a PE ratio of -7.21 and a beta of 2.48. The stock has a 50-day moving average price of $8.91 and a 200 day moving average price of $5.73.</p>
<div class="lb-trans"><p>该公司的市值为 10.3 亿美元，市盈率为-7.21，贝塔值为 2.48。该股票的 50 日移动平均价格为 8.91 美元，200 日移动平均价格为 5.73 美元。</p>
</div><p>Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. As a group, equities analysts predict that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Omeros（纳斯达克代码：OMER - 获取免费报告）最近在 11 月 13 日（星期四）发布了季度财报。这家生物制药公司报告的每股收益为（0.19 美元），超出市场共识预期的（0.58 美元）0.39 美元。整体来看，股票分析师预测 Omeros Corporation 在当前财政年度的每股收益将为-3.09 美元。</p>
</div><h2>Hedge Funds Weigh In On Omeros</h2>
<div class="lb-trans"><h2>对 Omeros 的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 5,677 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Omeros during the first quarter worth $88,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Omeros in the second quarter valued at about $32,000. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 829.6% in the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. acquired a new position in Omeros during the second quarter worth about $40,000. Institutional investors and hedge funds own 48.79% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该公司的持仓进行了调整。拉塞尔投资集团在第三季度将其在 Omeros 的持仓增加了 113.1%。拉塞尔投资集团现在拥有 10,695 股这家生物制药公司的股票，价值 44,000 美元，此前在上个季度又购买了 5,677 股。Trexquant Investment LP 在第一季度购买了 Omeros 的新股份，价值 88,000 美元。B. Riley Wealth Advisors Inc.在第二季度收购了 Omeros 的新股份，价值约 32,000 美元。Tower Research Capital LLC TRC 在第二季度将其在 Omeros 的持仓增加了 829.6%。Tower Research Capital LLC TRC 现在拥有 13,414 股这家生物制药公司的股票，价值 40,000 美元，此前在上个季度又购买了 11,971 股。最后，Sei Investments Co.在第二季度收购了 Omeros 的新股份，价值约 40,000 美元。机构投资者和对冲基金持有该公司 48.79% 的股票。</p>
</div><h2>About Omeros</h2>
<div class="lb-trans"><h2>关于 Omeros</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.</p>
<div class="lb-trans"><p>Omeros Corporation 是一家临床阶段的生物制药公司，专注于小分子和蛋白质治疗药物的发现、开发和商业化。该公司的研究项目针对炎症、补体介导的疾病和中枢神经系统疾病。Omeros 的产品组合包括内部发现的分子和生物制剂，反映了其推进满足医疗需求高的疾病治疗的承诺。</p>
</div><p>Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.</p>
<div class="lb-trans"><p>Omeros 首个获得 FDA 批准的产品 Omidria®（苯肾上腺素和氟氯噻吨眼内溶液）旨在通过防止手术中瞳孔缩小和减少接受白内障手术患者的术后疼痛来维持瞳孔大小。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Omeros</li>
<li>Washington prepares for war</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Nvidia x 1,000,000</li>
<li>$100 Trillion “AI Metal” Found in American Ghost Town</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Omeros 更好</li>
<li>华盛顿为战争做准备</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>Nvidia x 1,000,000</li>
<li>在美国鬼城发现了 100 万亿美元的 “人工智能金属”</li>
<li>在 1 月 1 日之前将 1,000 美元投入这只股票【不是 NVDA】</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Omeros Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Omeros 吗？</h2>
</div><p>Before you consider Omeros, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Omeros 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Omeros 并不在名单上。</p>
</div><p>While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Omeros 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

奥麦罗制药（NASDAQ:OMER）交易量大幅增加 - 仍然值得购买吗？